Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Ning

Showing results (971-980 of 997) with videos related to

Pageof 100
Sort By:
Nature Nanotechnology|March 24, 2026
Universal logical operations in a silicon quantum processorChunhui Zhang, Feng Xu, Shihang Zhang, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Military Medical Research|October 15, 2025
Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: a real-world multicenter studyChao Zheng, Guo-Chao Zhang, Long Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Chinese Journal of Integrative Medicine|June 9, 2022
Evaluation of Renal Impairment in Patients with Diabetic Kidney Disease by Integrated Chinese and Western MedicineYi-Lun Qu, Zhe-Yi Dong, Hai-Mei Cheng, et al.
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression OmnibusYu-Ning Huang, Pooja Vinod Jaiswal, Anushka Rajesh, et al.
Genome Biology|September 9, 2025
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus data repositoryYu-Ning Huang, Pooja Vinod Jaiswal, Anushka Rajes, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Pageof 100

Showing results (971-980 of 997) with videos related to

Sort By:
Pageof 100
Nature Nanotechnology|March 24, 2026
Universal logical operations in a silicon quantum processorChunhui Zhang, Feng Xu, Shihang Zhang, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Military Medical Research|October 15, 2025
Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: a real-world multicenter studyChao Zheng, Guo-Chao Zhang, Long Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Chinese Journal of Integrative Medicine|June 9, 2022
Evaluation of Renal Impairment in Patients with Diabetic Kidney Disease by Integrated Chinese and Western MedicineYi-Lun Qu, Zhe-Yi Dong, Hai-Mei Cheng, et al.
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression OmnibusYu-Ning Huang, Pooja Vinod Jaiswal, Anushka Rajesh, et al.
Genome Biology|September 9, 2025
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus data repositoryYu-Ning Huang, Pooja Vinod Jaiswal, Anushka Rajes, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Pageof 100